Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

In TRD Data’s tally of the biggest project filings of 2024, office-to-residential conversions took four of the top five spots ...

Guggenheim analysts adjusted Pfizer’s (NYSE:PFE) outlook, lowering the company’s price target from $35 to $33 while ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

Brown is a past board member of the chamber, which wields influence in state politics. Its nearly 60-member board boasts an ...

Pfizer (PFE) closed the latest trading day at $25.23, indicating a -1.33% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.82%. Meanwhile, the Dow ...

Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.